Inhaled Isopropyl Alcohol for Treatment of Nausea

Launched by STATE UNIVERSITY OF NEW YORK AT BUFFALO · Jun 12, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the use of inhaled isopropyl alcohol as a potential treatment for nausea and vomiting in children. Researchers want to find out if this method is effective compared to a standard medication called ondansetron or a placebo (a treatment that has no active ingredients). The trial is taking place in a pediatric emergency department and is currently recruiting participants.

To be eligible for this trial, children aged 7 to 17 years who weigh at least 15 kg and have moderate to severe nausea (rated 4 out of 10 or higher on a specific scale) can participate. However, some children may not qualify if they need intravenous (IV) access, have trouble breathing through their nose, or have certain medical conditions, among other reasons. If chosen to participate, children will be given either the inhaled isopropyl alcohol, ondansetron, or a placebo and monitored to see how well it helps with their nausea. This trial aims to explore a new option for relief in pediatric patients who often struggle with these uncomfortable symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with a chief complaint of nausea or vomiting
• • Ages 7-178 years, both sexes
• • Weight ≥ 15 kg
• • Baxter Animated Retching Faces (BARF) nausea severity score ≥ 4/10
• Exclusion Criteria:
• • 1. Require IV access
• • Inability to breathe in/out through the nose
• • Anosmia (self- or parental report)
• • Allergy to isopropyl alcohol or ondansetron
• • Current or history of alcohol abuse
• • Inability to communicate feeling nauseous
• • Inability to follow directions regarding taking deep breaths through the nose
• • Known prolonged QT interval
• • Pregnancy
• • Received antiemetics within the last 8 hours
• • Currently taking apomorphine